Cash, Revenue and regulatory milestones
GENinCode (LSE:GENI), the AIM-quoted genetic risk assessment company, published its half-year report on 29 September 2026. Revenue fell, losses narrowed and the company said its cash should last into the first quarter of 2027. This article examines how GENinCode reached that runway estimate, why revenue declined and what milestones it is relying on before its funds run down.
What GENinCode does
GENinCode develops genetic tests designed to assess an individual's risk of cardiovascular disease and other conditions. Its products include CARDIO inCode-Score, a polygenic risk test for coronary artery disease, and LIPID inCode, which the company says has been onboarded at more than 80 US institutional sites. It also works with the NHS on ROCA, a test related to the risk of ovarian cancer. Spain is its largest market, and the company has a Manufacturing and distribution Partnership with Thermo Fisher. Matthew Walls is chief executive.
The half-year report
On 29 September 2026, GENinCode reported revenue of £1.1m for the six months to 30 June 2026, down from £1.6m. The company said "revenues reduced mainly due to NHS cutbacks and the non-recurring Catalonia pilot study undertaken in H1 2025." Spain contributed £902,000, while the US and UK generated £53,000 and £47,000 respectively. Gross Margin fell to 47.5% from 53.0%.
Cost control narrowed the adjusted EBITDA loss to £2.26m from £2.54m, the operating loss reduced to £2.54m from £2.97m, and the loss before tax was £2.52m against £2.97m. The basic loss per share fell to 0.38p from 1.19p, reflecting the larger number of shares in issue after this year's fundraising. Mr Walls said the company "had hoped to achieve greater commercial traction with a launch of testing with Thermo Fisher but this is now expected later in the year."
Funding and the runway
Cash at 30 June 2026 was £2.0m, compared with £0.8m at 31 December 2025. The increase followed a February 2026 fundraising of about £4.66m gross through the issue of around 466 million shares at 1p. The report stated: "The Company expects cash runway to Q1 2027." Looking at the full year, it said it now expects full-year revenue of approximately £3.2m, with a reduced impact on adjusted EBITDA following significant cost reductions over the year.
On the regulatory side, the company said it "expects to finalise FDA 'De Novo' filing for CARDIO inCode-Score" in November 2026, with an EU IVDR filing expected in December 2026. It also cited US guideline recognition from the ACC/AHA. It reported that clinical validation by Kaiser Permanente has been completed. On 30 September 2026, a holding notification showed Armstrong Investments had increased its stake to about 5.50% of voting rights.
Risks to monitor
The most pressing issue is funding. A runway to the first quarter of 2027 implies that GENinCode is likely to need further capital, or substantially higher revenue, within months. Achieving £3.2m of revenue for the year would require a much better second half than the first, which depends on the delayed Thermo Fisher launch and on clinical adoption in Spain. NHS funding pressures have already reduced UK revenue to a small share of group revenue. Regulatory filings in the US and Europe carry timing risk, and approval is not assured. Any new fundraising could dilute existing shareholders further, as the February placing at 1p per share did.
Conclusion
GENinCode expects its cash to last into early 2027 because the £2.0m it held at the half-year, combined with cost reductions that narrowed losses, extends its resources for several more months. However, revenue fell in the first half, and the company's plans now rest on the Thermo Fisher launch, its FDA and EU filings and access to further funding.






Please wait processing your request...